<p>Context Therapeutics Inc. (NASDAQ:CNTX - 免费报告) - HC Wainwright 在 5 月 7 日向投资者发布的报告中下调了对 Context Therapeutics 2030 财年的每股收益 (EPS) 预期。HC Wainwright 分析师 E. Bodnar 现在预测该公司今年每股收益为 0.06 美元，低于之前预测的 0.08 美元。市场普遍预期 Context Therapeutics 当前全年的每股收益为 -0.49 美元。</p>
<p>CNTX 已成为其他几份研究报告的主题。Piper Sandler 将 Context Therapeutics 的目标价从 4.00 美元上调至 7.00 美元，并在 3 月 24 日的报告中给予该公司 “增持” 评级。华尔街 Zen 在 3 月 29 日的研究报告中将 Context Therapeutics 的评级从 “持有” 下调至 “卖出”。Guggenheim 在 3 月 24 日的报告中重申了 “买入” 评级，并设定了 5.00 美元的目标价。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Context Therapeutics 的 “卖出 (d-)” 评级。最后，Lifesci Capital 在 2 月 23 日的研究报告中将 Context Therapeutics 的股票评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 6.60 美元。</p>
<p>获取 <strong>Context Therapeutics</strong> 的提醒：</p>
<p><strong>获取我们关于 Context Therapeutics 的最新股票报告</strong></p>
<h2>Context Therapeutics 股票表现</h2>
<p>NASDAQ:CNTX 的股票在周五开盘价为 2.31 美元。该公司的 50 日移动平均线为 2.62 美元，200 日移动平均线为 1.90 美元。该公司的市值为 2.1178 亿美元，市盈率为 -5.48，贝塔值为 1.57。Context Therapeutics 的 52 周低点为 0.49 美元，52 周高点为 3.62 美元。</p>
<p>Context Therapeutics (NASDAQ:CNTX - 获取免费报告) 最近在 5 月 6 日发布了其财报。该公司报告季度每股收益为 -0.09 美元，超出分析师普遍预期的 -0.12 美元，超出幅度为 0.03 美元。</p>
<h2>Context Therapeutics 的机构交易</h2>
<p>几家机构投资者最近对该公司的持股进行了调整。Sanctuary Advisors LLC 在第一季度购买了 Context Therapeutics 的新股份，价值 51,000 美元。Virtu Financial LLC 在第四季度购买了 Context Therapeutics 的新股份，价值 43,000 美元。XTX Topco Ltd 在第四季度将其在 Context Therapeutics 的持股增加了 858.8%。XTX Topco Ltd 现在拥有该公司 101,605 股股票，价值 149,000 美元，此前在此期间又购买了 91,008 股。Quadrature Capital Ltd 在第四季度购买了 Context Therapeutics 的新股份，价值约 68,000 美元。最后，Millennium Management LLC 在第四季度购买了 Context Therapeutics 的新股份，价值约 3,824,000 美元。机构投资者持有该公司 14.03% 的股份。</p>
<h2>关于 Context Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Context Therapeutics NASDAQ: CNTX 是一家临床阶段的生物制药公司，专注于为基因定义的肿瘤患者群体发现和开发精准治疗。该公司的研究模型集中在识别新靶点和设计小分子及生物候选药物，以应对肿瘤生长和耐药性的关键驱动因素。Context Therapeutics 利用生物标志物驱动的方法，最大化临床反应的概率，针对实体肿瘤内特定分子亚群体量身定制其开发计划。</p>
<p>随着管线在早期临床试验中推进，Context Therapeutics 强调战略合作和学术伙伴关系，以加速实验室发现向以患者为中心的研究的转化。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Context Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Context Therapeutics 吗？</h2>
<p>在你考虑投资 Context Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 Context Therapeutics 并不在名单上。</p>
<p>虽然 Context Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CNTX

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

<p>HC Wainwright 已将 Context Therapeutics Inc.（NASDAQ:CNTX）2030 财年每股收益预期从 0.08 美元下调至 0.06 美元。该公司当前全年的共识预期每股收益为 -0.49 美元。多位分析师对 CNTX 的评级不一，其中包括一项强力买入评级、六项买入评级和一项卖出评级。该股开盘价为 2.31 美元，市值为 2.1178 亿美元，52 周价格区间为 0.49 至 3.62 美元。机构投资者持有该公司 14.03% 的股份</p>

<p>Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for Context Therapeutics in a note issued to investors on Thursday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of $0.06 per share for the year, down from their prior forecast of $0.08. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.49) per share.</p>
<div class="lb-trans"><p>Context Therapeutics Inc. (NASDAQ:CNTX - 免费报告) - HC Wainwright 在 5 月 7 日向投资者发布的报告中下调了对 Context Therapeutics 2030 财年的每股收益 (EPS) 预期。HC Wainwright 分析师 E. Bodnar 现在预测该公司今年每股收益为 0.06 美元，低于之前预测的 0.08 美元。市场普遍预期 Context Therapeutics 当前全年的每股收益为 -0.49 美元。</p>
</div><p>CNTX has been the topic of several other research reports. Piper Sandler raised their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, March 24th. Wall Street Zen lowered Context Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, March 29th. Guggenheim restated a &#34;buy&#34; rating and set a $5.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Context Therapeutics in a research note on Monday, April 20th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a &#34;strong-buy&#34; rating in a research report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $6.60.</p>
<div class="lb-trans"><p>CNTX 已成为其他几份研究报告的主题。Piper Sandler 将 Context Therapeutics 的目标价从 4.00 美元上调至 7.00 美元，并在 3 月 24 日的报告中给予该公司 “增持” 评级。华尔街 Zen 在 3 月 29 日的研究报告中将 Context Therapeutics 的评级从 “持有” 下调至 “卖出”。Guggenheim 在 3 月 24 日的报告中重申了 “买入” 评级，并设定了 5.00 美元的目标价。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Context Therapeutics 的 “卖出 (d-)” 评级。最后，Lifesci Capital 在 2 月 23 日的研究报告中将 Context Therapeutics 的股票评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 6.60 美元。</p>
</div><p>Get <strong>Context Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Context Therapeutics</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Report on Context Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Context Therapeutics 的最新股票报告</strong></p>
</div><h2>Context Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Context Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ:CNTX opened at $2.31 on Friday. The company has a fifty day moving average of $2.62 and a 200-day moving average of $1.90. The company has a market capitalization of $211.78 million, a PE ratio of -5.48 and a beta of 1.57. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62.</p>
<div class="lb-trans"><p>NASDAQ:CNTX 的股票在周五开盘价为 2.31 美元。该公司的 50 日移动平均线为 2.62 美元，200 日移动平均线为 1.90 美元。该公司的市值为 2.1178 亿美元，市盈率为 -5.48，贝塔值为 1.57。Context Therapeutics 的 52 周低点为 0.49 美元，52 周高点为 3.62 美元。</p>
</div><p>Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.03.</p>
<div class="lb-trans"><p>Context Therapeutics (NASDAQ:CNTX - 获取免费报告) 最近在 5 月 6 日发布了其财报。该公司报告季度每股收益为 -0.09 美元，超出分析师普遍预期的 -0.12 美元，超出幅度为 0.03 美元。</p>
</div><h2>Institutional Trading of Context Therapeutics</h2>
<div class="lb-trans"><h2>Context Therapeutics 的机构交易</h2>
</div><p>Several institutional investors have recently made changes to their positions in the company. Sanctuary Advisors LLC bought a new stake in Context Therapeutics during the first quarter worth $51,000. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd boosted its stake in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company's stock worth $149,000 after purchasing an additional 91,008 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Context Therapeutics during the fourth quarter valued at about $68,000. Finally, Millennium Management LLC bought a new position in shares of Context Therapeutics in the fourth quarter valued at approximately $3,824,000. Institutional investors own 14.03% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近对该公司的持股进行了调整。Sanctuary Advisors LLC 在第一季度购买了 Context Therapeutics 的新股份，价值 51,000 美元。Virtu Financial LLC 在第四季度购买了 Context Therapeutics 的新股份，价值 43,000 美元。XTX Topco Ltd 在第四季度将其在 Context Therapeutics 的持股增加了 858.8%。XTX Topco Ltd 现在拥有该公司 101,605 股股票，价值 149,000 美元，此前在此期间又购买了 91,008 股。Quadrature Capital Ltd 在第四季度购买了 Context Therapeutics 的新股份，价值约 68,000 美元。最后，Millennium Management LLC 在第四季度购买了 Context Therapeutics 的新股份，价值约 3,824,000 美元。机构投资者持有该公司 14.03% 的股份。</p>
</div><h2>About Context Therapeutics</h2>
<div class="lb-trans"><h2>关于 Context Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.</p>
<div class="lb-trans"><p>Context Therapeutics NASDAQ: CNTX 是一家临床阶段的生物制药公司，专注于为基因定义的肿瘤患者群体发现和开发精准治疗。该公司的研究模型集中在识别新靶点和设计小分子及生物候选药物，以应对肿瘤生长和耐药性的关键驱动因素。Context Therapeutics 利用生物标志物驱动的方法，最大化临床反应的概率，针对实体肿瘤内特定分子亚群体量身定制其开发计划。</p>
</div><p>With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.</p>
<div class="lb-trans"><p>随着管线在早期临床试验中推进，Context Therapeutics 强调战略合作和学术伙伴关系，以加速实验室发现向以患者为中心的研究的转化。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Context Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Context Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Context Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Context Therapeutics 吗？</h2>
</div><p>Before you consider Context Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Context Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 Context Therapeutics 并不在名单上。</p>
</div><p>While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Context Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 对 Context Therapeutics 2030 财年收益的预估是多少？